Skip to main content
SpringerLink
Log in

Randomized Trial of Perindopril, Enalapril, Losartan and Telmisartan in Overweight or Obese Patients with Hypertension

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and Objectives

Obesity exacerbates hypertension and stimulates the renin–angiotensin–aldosterone system (RAAS). Full-dose RAAS inhibition could be a therapeutic option in overweight or obese patients with hypertension. This study compared four RAAS inhibitors at full therapeutic doses to determine their effect on blood pressure (BP) and cardiovascular risk factors in these patients.

Methods

We conducted a 24-week, single-blind, randomized, parallel-group study in 120 overweight or obese patients (body mass index ≥27 kg/m2) with hypertension, aged 18–60 years. The primary endpoint was the change in mean 24-h systolic BP and diastolic BP from baseline to study end. Central BP, arterial stiffness, and metabolic and cardiac indices were also investigated. Patients were randomly allocated to perindopril 10 mg/day, enalapril 20 mg/day, losartan 100 mg/day or telmisartan 80 mg/day. Nonpharmacological interventions were also recommended.

Results

Reductions in mean 24-h systolic BP (and diastolic BP) were all significant (p < 0.05 versus baseline) for perindopril, enalapril, losartan and telmisartan: systolic BP −22, −11, −12 and −15 mmHg, respectively; (and diastolic BP −13, −6, −13 and −12 mmHg, respectively). Aortic elasticity improved with perindopril and telmisartan. Perindopril was associated with the greatest reductions in central aortic BP and leptin levels [30 % versus 2 %, 7 % and 14 % with enalapril, losartan and telmisartan, respectively (all p < 0.05 versus perindopril)]. Reductions in other BP, echocardiographic, metabolic and anthropometric parameters occurred with all treatments.

Conclusion

Full-dose RAAS inhibition, particularly with perindopril, effectively reduces BP, improves arterial structure and regulates cardiovascular risk factors in overweight or obese patients with hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462–536.

    PubMed  Google Scholar 

  2. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121–58.

    Article  PubMed  CAS  Google Scholar 

  3. Schmieder RE, Gatzka C, Schachinger H, et al. Obesity as a determinant for response to antihypertensive treatment. BMJ. 1993;307(6903):537–40.

    Article  PubMed  CAS  Google Scholar 

  4. Jordan J, Engeli S. Obesity, hypertension, and cardiovascular health: is there anything poor Cassandra tries to tell us? J Hypertens. 2012;30(6):1103–5.

    Article  PubMed  CAS  Google Scholar 

  5. Schmieder RE, Rockstroh JK. Obesity and hypertension. Curr Opin Nephrol Hypertens. 1994;3(5):546–9.

    Article  PubMed  CAS  Google Scholar 

  6. Gortmaker SL, Swinburn BA, Levy D, et al. Changing the future of obesity: science, policy, and action. Lancet. 2011;378(9793):838–47.

    Article  PubMed  Google Scholar 

  7. Ludwig DS. Childhood obesity—the shape of things to come. N Engl J Med. 2007;357(23):2325–7.

    Article  PubMed  CAS  Google Scholar 

  8. MacMahon SW, Blacket RB, Macdonald GJ, et al. Obesity, alcohol consumption and blood pressure in Australian men and women. The National Heart Foundation of Australia Risk Factor Prevalence Study. J Hypertens. 1984;2(1):85–91.

    Article  PubMed  CAS  Google Scholar 

  9. Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17(10):904–10.

    Article  PubMed  Google Scholar 

  10. Dorresteijn JA, Visseren FL, Spiering W. Mechanisms linking obesity to hypertension. Obes Rev. 2012;13(1):17–26.

    Article  PubMed  CAS  Google Scholar 

  11. Kurukulasuriya LR, Stas S, Lastra G, et al. Hypertension in obesity. Med Clin North Am. 2011;95(5):903–17.

    Article  PubMed  Google Scholar 

  12. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983–92.

    Article  PubMed  Google Scholar 

  13. Jordan J, Yumuk V, Schlaich M, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens. 2012;30(6):1047–55.

    Article  PubMed  CAS  Google Scholar 

  14. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–8.

    Article  PubMed  CAS  Google Scholar 

  15. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006;48(1):80–6.

    Article  PubMed  CAS  Google Scholar 

  16. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145–53.

    Article  PubMed  CAS  Google Scholar 

  17. Kalil GZ, Haynes WG. Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertens Res. 2012;35(1):4–16.

    Article  PubMed  CAS  Google Scholar 

  18. Nakamura T, Kawachi K, Saito Y, et al. Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. Int Heart J. 2009;50(4):501–12.

    Article  PubMed  CAS  Google Scholar 

  19. Sharma AM, Pischon T, Engeli S, et al. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens. 2001;19(4):667–74.

    Article  PubMed  CAS  Google Scholar 

  20. Asmar R, Topouchian J, Pannier B, et al. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. J Hypertens. 2001;19(4):813–8.

    Article  PubMed  CAS  Google Scholar 

  21. Manrique C, Lastra G, Gardner M, et al. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am. 2009;93(3):569–82.

    Article  PubMed  CAS  Google Scholar 

  22. Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol. 2001;88(9 suppl):1L–20L.

    Article  PubMed  CAS  Google Scholar 

  23. Ceconi C, Francolini G, Olivares A, et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007;577:1–6.

    Article  PubMed  CAS  Google Scholar 

  24. Morishita T, Tsutsui M, Shimokawa H, et al. Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease. Jpn J Pharmacol. 2002;88(1):100–7.

    Article  PubMed  CAS  Google Scholar 

  25. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme (ACE) inhibitors reduce mortality in hypertension—a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone-system (RAAS) inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088–97.

    Article  PubMed  CAS  Google Scholar 

  26. Krysiak R, Sierant M, Marek B, et al. The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease. Endokrynol Pol. 2010;61(6):683–90.

    PubMed  CAS  Google Scholar 

  27. Krysiak R, Sierant M, Marek B, et al. The effect of angiotensin-converting enzyme inhibitors on plasma adipokine levels in normotensive patients with coronary artery disease. Endokrynol Pol. 2010;61(3):280–7.

    PubMed  CAS  Google Scholar 

  28. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther. 2005;3(1):15–29.

    Article  PubMed  CAS  Google Scholar 

  29. Ferrari R, Fox K. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate ‘EUROPA’ story. Drugs. 2009;69(3):265–77.

    Article  PubMed  CAS  Google Scholar 

  30. Fox KM. Management of coronary artery disease: implications of the EUROPA trial. Br J Cardiol. 2004;11(3):195–204.

    Google Scholar 

  31. Physicians’ desk reference. 58th ed. Montvale: PDR Network LLC, 2004.

  32. Morgan T, Anderson A. Duration of antihypertensive effect of perindopril (P), enalapril (E) and captopril (C). Hypertension. 1993;21(4):568.

    Google Scholar 

  33. Devissaguet JP, Ammoury N, Devissaguet M, et al. Pharmacokinetics of perindopril and its metabolites in healthy volunteers. Fundam Clin Pharmacol. 1990;4(2):175–89.

    Article  PubMed  CAS  Google Scholar 

  34. Guo W, Turlapaty P, Shen Y, et al. Clinical experience with perindopril in patients nonresponsive to previous antihypertensive therapy: a large US community trial. Am J Ther. 2004;11(3):199–205.

    Article  PubMed  Google Scholar 

  35. Stolarz-Skrzypek K, Thijs L, Richart T, et al. Blood pressure variability in relation to outcome in the International Database of Ambulatory Blood Pressure in Relation to Cardiovascular Outcome. Hypertens Res. 2010;33(8):757–66.

    Article  PubMed  Google Scholar 

  36. Blacher J, Asmar R, Djane S, et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension. 1999;33(5):1111–7.

    Article  PubMed  CAS  Google Scholar 

  37. Nedogoda S. Efficiency of perindopril in patients with arterial hypertension and obesity [in Russian]. Kardiologiia. 2011;51(11):38–44.

    PubMed  CAS  Google Scholar 

  38. Cordonnier DJ, Pinel N, Barro C, et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. J Am Soc Nephrol. 1999;10(6):1253–63.

    PubMed  CAS  Google Scholar 

  39. Hermans MP, Brichard SM, Colin I, et al. Long-term reduction of microalbuminuria after 3 years of angiotensin-converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients. Am J Med. 1992;92(4B):102S–7S.

    Article  PubMed  CAS  Google Scholar 

  40. Rodriguez-Granillo GA, Vos J, Bruining N, et al. Long-term effect of perindopril on coronary atherosclerosis progression (from the PERindopril’s Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study). Am J Cardiol. 2007;100(2):159–63.

    Article  PubMed  CAS  Google Scholar 

  41. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.

    Article  PubMed  Google Scholar 

  42. Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007;73:237–46.

    Article  PubMed  CAS  Google Scholar 

  43. Myers MG. A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose-Response Study Group. Can J Cardiol. 1996;12(11):1191–6.

    PubMed  CAS  Google Scholar 

  44. Tsoukas G, Anand S, Yang K. Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study. Am J Cardiovasc Drugs. 2011;11(1):45–55.

    Article  PubMed  CAS  Google Scholar 

  45. Ficek J, Kokot F, Chudek J, et al. Influence of antihypertensive treatment with perindopril, pindolol or felodipinon plasma leptin concentration in patients with essential hypertension. Horm Metab Res. 2002;34(11–12):703–8.

    Article  PubMed  CAS  Google Scholar 

  46. Harwood HJ Jr. The adipocyte as an endocrine organ in the regulation of metabolic homeostasis. Neuropharmacology. 2012;63:57–75.

    Article  PubMed  CAS  Google Scholar 

  47. Poggi L, Renucci JF, Denolle T. Treatment of essential hypertension in general practice: an open-label study of 47,351 French hypertensive patients treated for one year with perindopril. Can J Cardiol. 1994;10(Suppl):D21D–4D.

    Google Scholar 

  48. Jandrain B, Herbaut C, Depoorter JC, et al. Long-term (1 year) acceptability of perindopril in type II diabetic patients with hypertension. Am J Med. 1992;92(4B):91S–4S.

    Article  PubMed  CAS  Google Scholar 

  49. Andrejak M, Santoni JP, Carre A, et al. A double-blind comparison of perindopril and hydrochlorothiazide-amiloride in mild to moderate essential hypertension. Fundam Clin Pharmacol. 1991;5(3):185–92.

    Article  PubMed  CAS  Google Scholar 

  50. Marre M, Leye A. Effects of perindopril in hypertensive patients with or without type 2 diabetes mellitus, and with altered insulin sensitivity. Diabetes Vasc Dis Res. 2007;4(3):163–73.

    Article  Google Scholar 

  51. Bohlen L, Bienz R, Doser M, et al. Metabolic neutrality of perindopril: focus on insulin sensitivity in overweight patients with essential hypertension. J Cardiovasc Pharmacol. 1996;27(6):770–6.

    Article  PubMed  CAS  Google Scholar 

  52. Fogari R, Mugellini A, Zoppi A, et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens. 2002;15(4):316–20.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

No funding was provided for this study. S. Nedogoda has received honoraria from several companies, including Servier, Takeda, KRKA, Abbott, Novartis, Boehringer Ingelheim and Astra Zeneca. The other authors have no conflicts of interest to declare. The authors have no other relevant affiliations or financial involvement with any organization or entity in conflict with the subject matter or materials discussed in the manuscript, apart from those disclosed.

Author information

Authors and Affiliations

  1. Volgograd State Medical University, Volgograd, Russia

    Sergey V. Nedogoda, Alla A. Ledyaeva, Elena V. Chumachok, Vera V. Tsoma, Galina Mazina, Alla S. Salasyuk & Irina N. Barykina

Authors
  1. Sergey V. Nedogoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alla A. Ledyaeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elena V. Chumachok
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vera V. Tsoma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Galina Mazina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alla S. Salasyuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Irina N. Barykina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sergey V. Nedogoda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nedogoda, S.V., Ledyaeva, A.A., Chumachok, E.V. et al. Randomized Trial of Perindopril, Enalapril, Losartan and Telmisartan in Overweight or Obese Patients with Hypertension. Clin Drug Investig 33, 553–561 (2013). https://doi.org/10.1007/s40261-013-0094-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-013-0094-9

Keywords

Search

Navigation